References
- Dimetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001; 28 (suppl 17): 19-26.
- Heinrich M, Griffith D J, Druker B J, Wait C L, Ott K A, Zigler A J. Inhibition of C-kit receptor tyrosine kinase activ-ity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925–932.
- Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor ima-tinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001; 33: 451–455.
- Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon. A clinicopathologic, immunohistochemical and molecu-lar genetic study of 44 cases. Am J Surg Pathol 2000; 24 (10): 1339-1352.
- Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1990; 63: 185–194.
- Wang L, Vargas H, French SW. Cellular origin of gas-trointestinal stromal tumors. A study of 27 cases. Arch Pathol Lab Med 2000; 124: 1471–1475.
- Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297–4300.
- Joensuu H, Robert P J, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor 5TI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344 (14): 1052–1056.
- Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (5TI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-23.
- Mayerhofer K, Obermairn A, Windbichler G, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999; 74: 196–201.
- De Vita VT, Hellman S, Rosemberg SA. Cancer, Principles and Practice of Oncology. 5th Edition, Lippincott - Raven, Philadelphia - New York, 1997: 333-347
- Gadducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996; 62 (1): 25–32.
- De Paco G, Stefanon B, Raspaglieli F. Neoplasie del corpo dell'utero in Bonadonna G, Robustelli della Cuna G. Medicina oncologica. (6th edition), Masson, Milano-Paris-Barcellona, 1999.
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
- Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblas-tic leukemia with the philadelphia chromosome. N Eng J Med 2001; 344: 1038–1042.
- Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutation in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 53–60.
- Lux ML, Rubin BP, Biase TL, et al. Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791–795.